Condition: Advanced Solid Tumor · Sponsor: ABL Bio, Inc.
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation study of ABL103 to evaluate the safety, tolerability, MTD (maximum tolerated dose) and/or RP2D (recommended phase 2 dose), pharmacokinetics, immunogenicity, preliminary antitumor activity of ABL103 in subjects with any progressive locally advanced(unresectable) or metastatic solid tumor who are relapsed or refractory following the last line of treatment and have no available standard of care option. This study includes 2 parts: a dose-escalation part and tumor-expansion part
This description comes directly from the study's public registry record.
Sangmi Le · +82-31-8014-7030 · sangmi.lee@ablbio.com
Jungwoo Choi · +82-31-8018-9857 · jungwoo.choi@ablbio.com
Always discuss trial participation with your own doctor first.
| Seoul National University Bundang Hospital | Seongnam, Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, Seoul, South Korea | Not Yet Recruiting |
| Sevrance Hospital | Seoul, South Korea, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06126666